ARCUTIS BIOTHERAPEUTICS, INC. Research and Development Expense
ARCUTIS BIOTHERAPEUTICS, INC. (ARQT) reported Research and Development Expense of $20.36 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-05
- ARCUTIS BIOTHERAPEUTICS, INC. research and development expense for the quarter ending 2026-06-30 was $20.36M, a 4.64% increase year-over-year.
- ARCUTIS BIOTHERAPEUTICS, INC. research and development expense for the quarter ending 2026-03-31 was $30.63M, a 74.58% increase year-over-year.
- ARCUTIS BIOTHERAPEUTICS, INC. research and development expense for the quarter ending 2025-12-31 was $20.45M, a 41.24% increase year-over-year.
- ARCUTIS BIOTHERAPEUTICS, INC. research and development expense for the quarter ending 2025-09-30 was $19.60M, a 0.53% increase year-over-year.
- ARCUTIS BIOTHERAPEUTICS, INC. research and development expense for fiscal 2025 was $77.05M, a 0.83% increase from fiscal 2024.
- ARCUTIS BIOTHERAPEUTICS, INC. research and development expense for fiscal 2024 was $76.42M, a 30.89% decline from fiscal 2023.
- ARCUTIS BIOTHERAPEUTICS, INC. research and development expense for fiscal 2023 was $110.58M, a 39.39% decline from fiscal 2022.
- ARCUTIS BIOTHERAPEUTICS, INC. research and development expense for fiscal 2022 was $182.44M, a 25.33% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $20.36M 10-Q · filed 2026-08-05 | $50.98M 10-Q · filed 2026-08-05 | $71.43M derived: sum of 3 quarters · filed 2026-08-05 | $91.04M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $30.63M 10-Q · filed 2026-05-06 | $51.08M derived: sum of 2 quarters · filed 2026-05-06 | $70.68M derived: sum of 3 quarters · filed 2026-05-06 | $90.14M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $20.45M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $40.05M derived: sum of 2 quarters · filed 2026-02-25 | $59.51M derived: sum of 3 quarters · filed 2026-08-05 | $77.05M 10-K · filed 2026-02-25 |
| 2025-09-30 | $19.60M 10-Q · filed 2025-10-28 | $39.06M derived: sum of 2 quarters · filed 2026-08-05 | $56.60M 10-Q · filed 2025-10-28 | $71.08M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $19.45M 10-Q · filed 2026-08-05 | $37.00M 10-Q · filed 2026-08-05 | $51.48M derived: sum of 3 quarters · filed 2026-08-05 | $70.98M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $17.54M 10-Q · filed 2026-05-06 | $32.02M derived: sum of 2 quarters · filed 2026-05-06 | $51.52M derived: sum of 3 quarters · filed 2026-05-06 | $70.82M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $14.48M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $33.98M derived: sum of 2 quarters · filed 2026-02-25 | $53.28M derived: sum of 3 quarters · filed 2026-02-25 | $76.42M 10-K · filed 2026-02-25 |
| 2024-09-30 | $19.50M 10-Q · filed 2025-10-28 | $38.80M derived: sum of 2 quarters · filed 2025-10-28 | $61.94M 10-Q · filed 2025-10-28 | $85.72M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-06-30 | $19.30M 10-Q · filed 2025-08-06 | $42.44M 10-Q · filed 2025-08-06 | $66.21M derived: sum of 3 quarters · filed 2026-02-25 | $92.45M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-03-31 | $23.14M 10-Q · filed 2025-05-06 | $46.92M derived: sum of 2 quarters · filed 2026-02-25 | $73.15M derived: sum of 3 quarters · filed 2026-02-25 | $98.37M derived: sum of 4 quarters · filed 2026-02-25 |
| 2023-12-31 | $23.77M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $50.01M derived: sum of 2 quarters · filed 2026-02-25 | $75.23M derived: sum of 3 quarters · filed 2026-02-25 | $110.58M 10-K · filed 2026-02-25 |
| 2023-09-30 | $26.24M 10-Q · filed 2024-11-06 | $51.45M derived: sum of 2 quarters · filed 2024-11-06 | $86.80M 10-Q · filed 2024-11-06 | $120.68M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-06-30 | $25.22M 10-Q · filed 2024-08-14 | $60.56M 10-Q · filed 2024-08-14 | $94.44M derived: sum of 3 quarters · filed 2025-02-25 | $164.17M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-03-31 | $35.34M 10-Q · filed 2024-05-14 | $69.22M derived: sum of 2 quarters · filed 2025-02-25 | $138.95M derived: sum of 3 quarters · filed 2025-02-25 | $177.16M derived: sum of 4 quarters · filed 2025-02-25 |
| 2022-12-31 | $33.88M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $103.61M derived: sum of 2 quarters · filed 2025-02-25 | $141.81M derived: sum of 3 quarters · filed 2025-02-25 | $182.44M 10-K · filed 2025-02-25 |
| 2022-09-30 | $69.73M 10-Q · filed 2023-11-03 | $107.94M derived: sum of 2 quarters · filed 2023-11-03 | $148.56M 10-Q · filed 2023-11-03 | $201.12M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | $38.20M 10-Q · filed 2023-08-08 | $78.83M 10-Q · filed 2023-08-08 | $131.38M derived: sum of 3 quarters · filed 2024-02-27 | $171.99M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | $40.62M 10-Q · filed 2023-05-09 | $93.18M derived: sum of 2 quarters · filed 2024-02-27 | $133.78M derived: sum of 3 quarters · filed 2024-02-27 | $164.55M derived: sum of 4 quarters · filed 2024-02-27 |
| 2021-12-31 | $52.56M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $93.16M derived: sum of 2 quarters · filed 2024-02-27 | $123.93M derived: sum of 3 quarters · filed 2024-02-27 | $145.56M 10-K · filed 2024-02-27 |
| 2021-09-30 | $40.60M 10-Q · filed 2022-11-08 | $71.37M derived: sum of 2 quarters · filed 2022-11-08 | $93.00M 10-Q · filed 2022-11-08 | $120.37M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | $30.77M 10-Q · filed 2022-08-04 | $52.40M 10-Q · filed 2022-08-04 | $79.77M derived: sum of 3 quarters · filed 2023-02-28 | $112.51M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | $21.63M 10-Q · filed 2022-05-05 | $49.01M derived: sum of 2 quarters · filed 2023-02-28 | $81.75M derived: sum of 3 quarters · filed 2023-02-28 | $111.76M derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | $27.37M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $60.12M derived: sum of 2 quarters · filed 2023-02-28 | $90.13M derived: sum of 3 quarters · filed 2023-02-28 | $115.31M 10-K · filed 2023-02-28 |
| 2020-09-30 | $32.74M 10-Q · filed 2021-11-04 | $62.75M derived: sum of 2 quarters · filed 2021-11-04 | $87.93M 10-Q · filed 2021-11-04 | $98.69M derived: sum of 4 quarters · filed 2022-02-22 |
| 2020-06-30 | $30.01M 10-Q · filed 2021-08-05 | $55.19M 10-Q · filed 2021-08-05 | $65.95M derived: sum of 3 quarters · filed 2022-02-22 | $78.30M derived: sum of 4 quarters · filed 2022-02-22 |
| 2020-03-31 | $25.18M 10-Q · filed 2021-05-06 | $35.94M derived: sum of 2 quarters · filed 2022-02-22 | $48.29M derived: sum of 3 quarters · filed 2022-02-22 | $55.50M derived: sum of 4 quarters · filed 2022-02-22 |
| 2019-12-31 | $10.76M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-22 | $23.11M derived: sum of 2 quarters · filed 2022-02-22 | $30.32M derived: sum of 3 quarters · filed 2022-02-22 | $36.52M 10-K · filed 2022-02-22 |
| 2019-09-30 | $12.35M 10-Q · filed 2020-11-05 | $19.56M derived: sum of 2 quarters · filed 2020-11-05 | $25.77M 10-Q · filed 2020-11-05 | |
| 2019-06-30 | $7.21M 10-Q · filed 2020-08-11 | $13.42M 10-Q · filed 2020-08-11 | ||
| 2019-03-31 | $6.20M 10-Q · filed 2020-05-12 | |||
| 2018-12-31 | $17.94M 10-K · filed 2021-02-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 |